Compare Amylx Pharmaceuticals Inc (AMLX) vs Capri Holdings Ltd (CPRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Capri Holdings Ltd — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Capri Holdings Ltd trades at $18.04 (market cap $2.07B). The key difference: Amylx Pharmaceuticals Inc and Capri Holdings Ltd are close in size by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| AMLX | CPRI | |
|---|---|---|
Market Cap | $1.98B | $2.07B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $27.66 |
52-Week Low | $7.64 | $16.79 |
Enterprise Value | $1.70B | $3.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
CPRI trades at $18.04, down 0.22% with bearish technical signals. The company reported mixed Q4 2026 results with an EPS beat but revenue challenges, while showing a net loss of $1.18 billion in 2025. Analyst consensus is divided with a $23.33 price target, and recent news highlights a post-Versace turnaround focus on Michael Kors and Jimmy Choo brands.
The outlook hinges on successful execution of brand revamps and cost controls. Key risks include luxury demand volatility and high debt, but current valuation metrics like P/S of 0.62 may offer value if the turnaround gains traction. Institutional sentiment is cautiously optimistic with 44% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →
